HighTide Therapeutics, Inc. (02511)
HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase IIb clinical trial to treat metabolic dysfunction-associated steatohepatitis (MASH); in phase II clinical trial
CS Hotline: +852 3018 4526
Trading days: 24 hours | Non-trading days: 9:00-18:00
